PE134999A1 - Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal - Google Patents

Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal

Info

Publication number
PE134999A1
PE134999A1 PE1998001138A PE00113898A PE134999A1 PE 134999 A1 PE134999 A1 PE 134999A1 PE 1998001138 A PE1998001138 A PE 1998001138A PE 00113898 A PE00113898 A PE 00113898A PE 134999 A1 PE134999 A1 PE 134999A1
Authority
PE
Peru
Prior art keywords
neuronal
diseases
aminometil
chromanes
impediment
Prior art date
Application number
PE1998001138A
Other languages
English (en)
Spanish (es)
Inventor
Ervin Horvath
Reinhard Jork
Thomas Fahrig
Irene Gerlach
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE134999A1 publication Critical patent/PE134999A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE1998001138A 1997-11-24 1998-11-23 Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal PE134999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19751949A DE19751949A1 (de) 1997-11-24 1997-11-24 Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration

Publications (1)

Publication Number Publication Date
PE134999A1 true PE134999A1 (es) 2000-03-05

Family

ID=7849618

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001138A PE134999A1 (es) 1997-11-24 1998-11-23 Uso de aminometil-cromanos sustituidos para el impedimento de la degeneracion neuronal y para el estimulo de la regeneracion neuronal

Country Status (30)

Country Link
US (2) US6235774B1 (enExample)
EP (1) EP1051170B1 (enExample)
JP (1) JP2001523716A (enExample)
KR (1) KR20010032357A (enExample)
CN (1) CN1134256C (enExample)
AR (1) AR016973A1 (enExample)
AT (1) ATE206615T1 (enExample)
AU (1) AU745759B2 (enExample)
BG (1) BG64167B1 (enExample)
CA (1) CA2311126A1 (enExample)
DE (2) DE19751949A1 (enExample)
DK (1) DK1051170T3 (enExample)
ES (1) ES2164465T3 (enExample)
HN (1) HN1998000169A (enExample)
HU (1) HUP0004369A3 (enExample)
IL (1) IL135904A (enExample)
IS (1) IS5496A (enExample)
MY (1) MY118414A (enExample)
NO (1) NO20002638D0 (enExample)
NZ (1) NZ504656A (enExample)
PE (1) PE134999A1 (enExample)
PL (1) PL340674A1 (enExample)
PT (1) PT1051170E (enExample)
RU (1) RU2217140C2 (enExample)
SI (1) SI1051170T1 (enExample)
SV (1) SV1998000138A (enExample)
TR (1) TR200001471T2 (enExample)
TW (1) TW524690B (enExample)
WO (1) WO1999026621A1 (enExample)
ZA (1) ZA9810668B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
MXPA02009071A (es) * 2000-03-17 2003-05-23 Alcon Inc Compuestos con actividad agonista de 5-ht 1a para tratar glaucoma..
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
DE10058119A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
SE0004455D0 (sv) * 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
DE10101917A1 (de) * 2001-01-16 2002-07-18 Bayer Ag Verwendung von Chromanen
BR0211358A (pt) * 2001-07-26 2004-09-21 Merck Patent Gmbh Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
KR100886185B1 (ko) * 2001-09-12 2009-02-27 메르크 파텐트 게엠베하 운동 장애의 치료 및 추체외로 운동 장애의 치료를 위해 투여된 약물에 의해 유도된 부작용의 치료를 위한 치환된 아미노메틸 크로만의 신규한 용도
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
CA2580584C (en) * 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
DE102004017627A1 (de) * 2004-04-10 2005-10-27 Bayer Healthcare Ag Verwendung von vollen 5-HT1A-Agonisten zur Hemmung der opiat/opioid-induzierten Atemdepression
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
RU2651756C1 (ru) * 2017-05-10 2018-04-23 Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ Препарат для предотвращения образования глиальных рубцов
JP7191085B2 (ja) * 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
US5300523A (en) 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
DE19522088A1 (de) 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration

Also Published As

Publication number Publication date
TW524690B (en) 2003-03-21
ES2164465T3 (es) 2002-02-16
KR20010032357A (ko) 2001-04-16
EP1051170A1 (de) 2000-11-15
HUP0004369A2 (hu) 2001-04-28
PT1051170E (pt) 2002-02-28
WO1999026621A1 (de) 1999-06-03
ZA9810668B (en) 1999-05-26
NO20002638L (no) 2000-05-23
DK1051170T3 (da) 2001-12-27
IS5496A (is) 2000-05-15
AU745759B2 (en) 2002-03-28
MY118414A (en) 2004-10-30
AU1668599A (en) 1999-06-15
CN1134256C (zh) 2004-01-14
DE19751949A1 (de) 1999-05-27
AR016973A1 (es) 2001-08-01
US6331561B2 (en) 2001-12-18
CA2311126A1 (en) 1999-06-03
BG64167B1 (bg) 2004-03-31
BG104466A (en) 2001-02-28
HN1998000169A (es) 1999-11-03
ATE206615T1 (de) 2001-10-15
EP1051170B1 (de) 2001-10-10
HUP0004369A3 (en) 2002-04-29
IL135904A0 (en) 2001-05-20
PL340674A1 (en) 2001-02-12
NZ504656A (en) 2002-02-01
TR200001471T2 (tr) 2000-10-23
IL135904A (en) 2003-07-06
CN1279604A (zh) 2001-01-10
JP2001523716A (ja) 2001-11-27
SI1051170T1 (en) 2001-12-31
RU2217140C2 (ru) 2003-11-27
NO20002638D0 (no) 2000-05-23
DE59801724D1 (de) 2001-11-15
US20010018530A1 (en) 2001-08-30
US6235774B1 (en) 2001-05-22
SV1998000138A (es) 1999-05-25

Similar Documents

Publication Publication Date Title
JP3553083B2 (ja) 末梢性活性抗痛覚過敏オピエート
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
BR0010869A (pt) Método para administrar um corticosteróide a um segmento posterior de um olho e dispositivo de liberação sustentada implantável
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
JP2003509164A5 (enExample)
JP2003529548A5 (enExample)
BR9808938A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
BRPI0820800B8 (pt) dispositivo médico implantável para liberação controlada de droga
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
DE69715049D1 (de) Tranilast enthaltendes externum und verfahren zu dessen herstellung
SI9111227B (sl) Farmacevtski preprat z aktivno materijo Flupirtin za zdravljenje bolezni, ki se nanašajo na napetost mišic
BR0107983A (pt) Uso de pramipexol para o tratamento de enfermidades decorrentes de vìcios
BR0210034A (pt) Conjunto de partes, método para tratamento de trombose, uso de um composto, formulação farmacêutica, uso e processo para preparação da mesma, e, composto
BR0210075A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou distúrbios da debilitação intelectual e de fadiga de vÈo, cessamento de fumar, dependência de nicotina, dores, e para a colite ulcerativa
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
DE50110262D1 (de) Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
BR9807796A (pt) Processos para tratar da incontinência urinária, de vertigem e da doença do movimento, e, composição farmacêutica.
BR0316040A (pt) Composto, métodos para tratar doenças, para tratar edema macular, degeneração macular, aumentar a velocidade do sangue retinal e da cabeça do nervo óptico, aumentar a tensão de oxigênio retinal e do nervo óptico e/ou um efeito neuroprotetor, para prevenir a repolarização ou a hiperpolarização de uma célula de mamìfero contendo canal de potássio, e para tratar do diabete, e, composição
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
MXPA02009881A (es) Nuevos medicamentos intracorporales para tratamiento fototerapeutico con alta energia de enfermedad.
BR9909478A (pt) Novos tratamentos para vários distúrbios do sistema nervoso
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
DE60130030D1 (de) Verfahren zur behandlung von glaukom

Legal Events

Date Code Title Description
FC Refusal